
Take-Two Interactive Software, Inc. closed Friday at $239.62, marking a 3.0% decrease from its previous weekly finish and erasing around $1.4 billion in equity value, according to preliminary estimates.
Consensus: Strong Buy. Twenty-seven of 28 recommendations are Buy or Strong Buy.
The market punished loss of marketing control, then bought the schedule. Thursday's August 27 extended preview is the next measurable checkpoint. Engagement and a firm November 19 release date matter more than the leaked clips themselves.
| Metric | Q2 FY26 | Q2 FY27 est. | Growth |
|---|---|---|---|
| Revenue | $46.7B | $92.16B | +97% |
| Adjusted EPS | $1.05 | $2.09 | +99% |
| Data Center | $41.1B | $85.67B | +108% |
| Data Center mix | 88% | 93% | +5 pts |
| Firm | View | Target | Upside |
|---|---|---|---|
| BMO | Outperform | $340 | 58% |
| RBC | Outperform | $300 | 40% |
| Morgan Stanley | Overweight | $288 | 34% |
| Oppenheimer | Outperform | $265 | 23% |
| Stifel | Buy | $282 | 31% |
Rates rose as expectations stayed high.
The semiconductor index lost about 5% last week. Nvidia fell every session as long-bond yields climbed. Friday’s reported server-price increase now adds an input-cost question before earnings.
| Stock | Market cap | TTM sales | P/S |
|---|---|---|---|
| QUBT | $2.02B | $9.82M | 206× |
| IONQ | $17.89B | $246.47M | 73× |
| RGTI | $5.98B | $13.35M | 448× |
| QBTS | $7.49B | $12.43M | 603× |
Sector rotation, not fresh company news.
QUBT rallied with IONQ, RGTI and QBTS after three declining sessions. The volume jump supports a risk-on move. The latest company earnings release remains the Aug. 10 Q2 report.
A close above $9.18 would strengthen the rebound. A break below $8.14 would return focus to execution, spending and order conversion.
Brent climbed 6.39% as Iran sanctions threats tightened the supply outlook.
BP offers more balance-sheet sensitivity than less-leveraged European peers.
Friday’s 0.49% dip showed some profit-taking after four stronger sessions.
Main downside: rapid geopolitical de-escalation, weaker oil, delayed disposals or another reliability setback.
| Reference | Level | Gap |
|---|---|---|
| 50-day average | $74.52 | +6.8% |
| 200-day average | $88.42 | −10.0% |
| 52-week high | $126.71 | −37.2% |
| 52-week low | $65.08 | +22.3% |
| Metric | Reading |
|---|---|
| Trailing P/E | 25.1× |
| Forward P/E | 23.0× |
| Trailing FCF | $11.15B |
| FCF margin | 23.1% |
| 2026 revenue guide | $51.0B–$51.4B |
| Blood Sacrifice | 5 episodes |
| Global launch | Aug. 20 |
| H1 Netflix viewing | >97B hours |
| Next checkpoint | Weekly Top 10 rank and staying power |
A country-level or global Top 10 debut would confirm discovery. Persistence would matter more. A short-lived UK ranking would not justify a revenue revision on its own.
| Target | Value | Vs. $344.82 |
|---|---|---|
| Consensus average | $428.04 | +24.13% |
| Low | $340 | −1.40% |
| High | $515 | +49.35% |
| Revenue test | Value |
|---|---|
| Q1 FY27 actual | $81.62B |
| Q2 guide midpoint | $91.00B |
| Q2 consensus | $92.16B |
| Street premium to guide | +1.27% |
| Expected adjusted EPS | $2.09 |
| Firm | Rating | Target | Upside |
|---|---|---|---|
| BMO Capital | Outperform | $340 | 58% |
| Benchmark | Buy | $335 | 56% |
| Oppenheimer | Buy | $265 | 23% |
| Consensus | Strong Buy | $304.73 | 42% |
| Metric | 2026 | Comparison |
|---|---|---|
| Cash & securities | $237.9m | −$80.2m in H1 |
| Q2 operating expense | $42.9m | +55.0% YoY |
| Q2 net loss | $40.7m | +57.2% YoY |
| Runway at H1 loss pace | ~19 months | Preliminary |
| Firm | Action | Rating | Target | Versus $6.29 |
|---|---|---|---|---|
| Cantor Fitzgerald | Upgrade | Buy | $28 | +345% |
| Piper Sandler | Maintain | Hold | $2 | −68% |
| B. Riley | Maintain | Hold | $5 | −21% |
| Consensus | — | Hold | $10.50 avg. | +67% |
| Median | — | — | $6 | −5% |
Digital software, add-ons and network services: ¥693.8bn, or 74.0% of Q1 gaming sales.
| Measure | Q1 FY25 | Q1 FY26 | Change |
|---|---|---|---|
| Gaming sales | ¥936.5bn | ¥937.1bn | +0.1% |
| Operating income | ¥148.0bn | ¥202.0bn | +36.5% |
| Operating margin | 15.8% | 21.6% | +5.8 pts |
| Monthly active users | 123m | 125m | +1.6% |
| PS5 units | 2.5m | 1.6m | −36.0% |
| Firm | Call | Target | Upside |
|---|---|---|---|
| JPMorgan | Buy | ¥5,800 | +53.2% |
| Nomura | Buy | ¥4,900 | +29.5% |
| Benchmark | Buy | ¥4,200 | +11.0% |
| Bernstein | Hold | ¥3,800 | +0.4% |
| Citi | Hold | ¥3,500 | −7.5% |
Tokyo close: ¥3,785 on Aug. 21, 2026.
Sources: Sony Group Q1 FY2026 presentation and supplemental information; PlayStation Blog; campaign organizers; MarketWatch; AP; Yahoo Japan; Investing.com. The boycott sensitivity discussed in the accompanying article is illustrative, not a forecast. Price data are time-stamped above.
Down 3% year on year. Recurrent consumer spending was 84% of bookings. GAAP revenue rose 2% to $1.53bn.
The company also guides to GAAP revenue of $7.9bn–$8.1bn and capital spending near $290m.
Further leaks, a weak reveal, cancellations, launch slippage or soft mobile bookings could challenge the bullish target range.
| Target | Price | Move from close |
|---|---|---|
| Low | $215 | -30.5% |
| Average | $326.34 | +5.5% |
| Median | $335 | +8.3% |
| High | $400 | +29.3% |
| What to watch | Verified baseline | Bull case | Risk |
|---|---|---|---|
| September product event | First-half September timing is reported, not official | Pro-first mix lifts average price | Delay or weaker premium demand |
| iPhone momentum | Q3 revenue +21.7% year over year | Upgrade cycle extends | Lower-priced models arrive later |
| Gross margin | 50.1%; about 2 points from tariff refunds | Mix offsets component costs | Underlying margin nearer 48.1% by simple subtraction |
| Street valuation | $326.34 average target | High target reaches $400 | Low target is $215 |
Market data: August 21, 2026, 4:00 p.m. EDT · U.S. market closed
Preliminary calculation from the August 18 high, August 20 low and Friday close. Price movement has multiple causes.
| Event | Date |
|---|---|
| Reported subpoenas filed | Aug. 20 |
| Official GTA VI extended look | Aug. 27 |
| Requested subpoena response | Sept. 4 |
| GTA VI launch | Nov. 19 |
The August 27 stream starts at 3 p.m. EDT on Netflix and 9 p.m. EDT on Rockstar channels.
| Measure | Value | Gap |
|---|---|---|
| Company low | $8.0bn | −9.7% |
| Company midpoint | $8.1bn | −8.6% |
| Company high | $8.2bn | −7.4% |
| Street estimate cited by Reuters | $8.86bn | Reference |
Guidance is unchanged despite unusually strong preorder demand.
| Firm | View | Target | Upside |
|---|---|---|---|
| BTIG | Buy | $313 | 30.6% |
| J.P. Morgan | Buy | $310 | 29.4% |
| Roth Capital | Buy | $300 | 25.2% |
| Wolfe Research | Buy | $289 | 20.6% |
| 28-analyst average | Strong Buy | $286.89 | 19.7% |
Risks: Rockstar has not fully authenticated the leaked material. Legal outcomes remain uncertain. GTA VI could face delays, weak preorder conversion, higher launch costs or softer engagement. Market-value estimates use an implied share count.
Market data: August 21, 2026, 4:00 p.m. EDT · U.S. market closed
The capped-ratio result is 2.16× the old model and equals 21.9% of Critical Metals’ June share count.
| Scheme VWAP | Ratio | Net shares |
|---|---|---|
| $8 or below | 0.045 | +32.1m |
| $12 | 0.035 | +14.9m |
| $16 or above | 0.025 | −2.4m |
The final ratio uses the specified 20-day VWAP, not one closing price.
| Firm | View | Target | Upside |
|---|---|---|---|
| Freedom Broker | Hold | $8 | 12.5% |
| Cantor Fitzgerald | Speculative Buy | $18 | 153.2% |
| Two-analyst average | Hold | $13 | 82.8% |
Targets are the latest available and may lag changing deal terms.
Risks: This is a preliminary quoted-share model. Options, performance rights, warrants and later capital changes are excluded. Completion still requires shareholder, option-holder and court approvals. Tanbreez also faces permitting, construction, financing, metallurgy and commodity-price risk.
Friday's rally followed the second box. Three consequential stages still remain.
SELLAS' rally now rests on an event-driven Phase 3 survival readout. Cash is meaningful, but it explains only 4.4% of market value.
SLS gained 54.4% across three consecutive winning weeks.
What Friday's equity value represents
No product revenue was reported for the first half of 2026.
REGAL is event-driven; the date cannot be fixed.
Statistically significant, clinically meaningful survival could support a potential BLA filing.
A missed survival endpoint would remove the main late-stage pillar beneath valuation.
Six months ended June 30, 2026
Weekly stock moves use August 14–21 closes. Targets are current S&P Global consensus data.
| Company | Weekly move | Consensus | Analysts | Average target | Implied return |
|---|---|---|---|---|---|
| Moderna · NASDAQ:MRNA | +129.2% | Hold | 23 | $91.39 | -37.0% |
| SELLAS · NASDAQ:SLS | +21.0% | Buy | 2 | $32.50 | +110.2% |
| Merck · NYSE:MRK | +12.3% | Buy | 28 | $147.77 | -3.1% |
| ImmunityBio · NASDAQ:IBRX | +2.9% | Strong Buy | 4 | $12.75 | +63.7% |
REGAL could miss its survival endpoint or face regulatory demands for more evidence. SLS009 remains early. Warrant exercises and future equity sales can dilute holders. A reversal in cancer-vaccine sentiment could erase gains before company-specific data arrive.
Stock data: August 21, 2026, 4:00 p.m. EDT. Dashboard status: August 22, 2026, 6:24 a.m. EDT. Sources: SELLAS SEC filings; ClinicalTrials.gov; Yahoo Finance; StockAnalysis. Peer programs differ in platform, indication and stage.
| Q2 metric | 2026 | YoY |
|---|---|---|
| Revenue | $108.5M | +89% |
| Adjusted EBITDA | $28.5M | +$41.0M |
| NdPr production | 840 MT | +41% |
| NdPr sales | 1,006 MT | +127% |
| REO production | 11,072 MT | -16% |
| Measure | Value | Vs. close |
|---|---|---|
| Low target | $58.00 | -3.4% |
| Average target | $75.38 | +25.5% |
| Median target | $75.00 | +24.9% |
| High target | $100.00 | +66.5% |
| Consensus | Strong Buy | 18 analysts |
Friday's 9.14% rebound left MP only 2.26% higher for the week. The operating case is improving, but the earnings bridge remains policy-sensitive: Q2 price-protection income equaled nearly two-thirds of adjusted EBITDA.
Rare-earth trade policy
Independence magnet qualification
10X construction progress
Follow-through after high-volume rally
Sources: Nasdaq market data; MP Materials Q2 2026 results; S&P Global analyst data via StockAnalysis, last updated August 19, 2026. Adjusted EBITDA is non-GAAP. Percentages are calculated from reported figures and may vary slightly due to rounding.
Moderna · NASDAQ:MRNA
Day range $132.42–$159.47 · Volume 86.74M vs. 15.08M average
$62.96 before the readout to $145.13 Friday.
$82.17 per share × 399.24M shares.
About 8.4× June cash and investments.
Before the $950M litigation payment made in July.
INTerpath-001 enrolled 1,137 melanoma patients and met recurrence-free and distant-metastasis-free survival endpoints. No new safety signal emerged. The full Phase 3 hazard ratios, confidence intervals, subgroup results and overall-survival data remain undisclosed. Investors have added $32.81 billion of equity value without the effect size.
Risk: the price can reverse if detailed efficacy, safety or regulatory timing falls short of the expectations embedded in the rally.
Sources: Google Finance · Phase 3 release · SEC Q2 filing
Today’s highest-ranked model selections.
The catalysts most likely to move markets.
This is the clearest scheduled U.S.-market price-discovery point today and can transmit weekend news into equity-index futures before Monday's cash session.
The Q2 retail package can move NZD and regional risk sentiment. Spillover to U.S. assets is usually secondary unless the result is unusually large.
The absence of U.S. releases, earnings, IPO pricings and split events leaves fewer scheduled catalysts, increasing the relative importance of weekend headlines and positioning at the futures reopen.